Please ensure Javascript is enabled for purposes of website accessibility

Maryland to share in Wyeth Pharmaceuticals $491 million settlement

Maryland will receive more than half a million dollars as its share of a $491 million settlement between drug maker Wyeth Pharmaceuticals Inc., and the federal government, all 50 states and the District of Columbia, Maryland Attorney General Douglas F. Gansler announced Wednesday.

The settlement resolves civil and criminal allegations that Wyeth, of Collegeville, Pa., promoted the sale and use of Rapamune, a kidney transplant drug, for uses that had not been approved by the Food and Drug Administration.

Maryland will recover $517,436 for the state Medicaid program, a portion of which will be returned to the federal government.